Visceral leishmaniasis in a patient with active HBV/HDV co-infection

J Infect Public Health. 2020 Feb;13(2):306-308. doi: 10.1016/j.jiph.2019.07.026. Epub 2019 Aug 13.

Abstract

Visceral leishmaniasis (VL) is an endemic infection in different regions of Italy and Europe caused by protozoan parasites of the genus Leishmania, transmitted to humans through sandflies bites. Reactivation after Solid Organ Transplantation was reported and could be a risk of organ rejection. A 48 years old woman was admitted to our hospital, complaining about low-grade fever, loss of weight and new onset pancytopenia in a known cirrhosis due to active HBV/HDV co-infection. Clinical, microbiological and anatomo-pathological elements were pivotal to define the diagnosis of VL and started an appropriate anti-infective treatment. After that she underwent liver transplantation and a therapy for VL was set. No signs of reactivation were reported in the 14 months of follow-up.

Keywords: HBV; HDV; Leishmaniasis; Liposomial amphotericin B; Pancytopenia; Solid organ transplant.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antiprotozoal Agents / therapeutic use
  • Biopsy
  • Bone Marrow / pathology
  • Coinfection / complications*
  • Coinfection / parasitology
  • Female
  • Hepatitis B / complications*
  • Hepatitis B / parasitology
  • Hepatitis D / complications*
  • Hepatitis D / parasitology
  • Humans
  • Italy
  • Leishmania / isolation & purification*
  • Leishmaniasis, Visceral / complications
  • Leishmaniasis, Visceral / diagnosis*
  • Leishmaniasis, Visceral / drug therapy
  • Leishmaniasis, Visceral / pathology
  • Liver Transplantation
  • Middle Aged
  • Pancytopenia / complications
  • Treatment Outcome

Substances

  • Antiprotozoal Agents
  • liposomal amphotericin B
  • Amphotericin B